Adding Pemetrexed to Gefitinib Improves PFS in EGFR-Mutated NSCLC

The combination of pemetrexed and gefitinib offered improved progression-free survival in East Asian patients with advanced nonsquamous NSCLC and activating EGFR mutations.

Source: CancerNetwork - August 8, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news